Background: We identified a new and a recurrent POLD1 mutation associated with predispo-
Results:
We included 32 individuals from the four families: 20 carriers and 12 noncarriers. A common haplotype was identified in these families in a region comprising 2,995 Mb, confirming L474P as the first founder POLD1 mutation identified. Thirteen tumors diagnosed in 10 POLD1 carriers: eight CRC, three endometrial and two other tumors were considered. The median age of cancer onset for POLD1 mutation carriers was 48 years. The observed penetrance was 50% and the cumulative risk at age of 50 years was 30%.
Conclusions:
The findings of the present study contribute to a better understanding of CRC genetics in the Spanish population. The clinical phenotype for this mutation is similar to that in Lynch syndrome. Future studies using next generation sequencing with large gene panels for any hereditary cancer condition will offer the possibility of detecting POLE/POLD1 mutations in unsuspected clinical situations, demonstrating a more real and unbiased picture of the associated phenotype. Pol ε (POLD1 and POLE, respectively). 1 A major role of Pol δ in both the leading and lagging DNA strands has been reported. 2 This new entity emerged from the findings of The Cancer Genome
Atlas project on colorectal cancer (CRC), in which a subset of ultramutated tumors with an absence of microsatellite instability (MSI) and recurrent somatic mutations in the POLE exonuclease domain was identified. 3 The number of germline POLD1/POLE proofreading domain mutations analyzed to date is relatively modest, and most cases were found to have microsatellite stable tumors, 1,4 even though MSI has been noted in some cases. 5 The most common Adela Castillejo and José-Luis Soto are contributed equally to this work.
germline mutations found to date are POLE L424 V and POLD1 S478 N, although an increasing number of other different pathogenic variants are being identified. 1 The PPAP phenotype overlaps that of Lynch syndrome (LS) and MUTYH-associated polyposis (MAP) and the proposed screening and management algorithms are broadly similar. The analysis of POLE and POLD1 is included in the diagnostic algorithm for these two cancer syndromes. 6 We previously reported a new pathogenic POLD1 variant (L474P)
in two independent families classified as having familial CRC type X. 6, 7 The finding of two other, apparently unrelated families from the same population prompted us to establish its founder effect and its phenotype description. 
| Germline mutation analysis
Germline mutation studies were performed on DNA isolated from peripheral blood leucocytes. Sanger sequencing was used to screen for mutations in exons where the most frequent mutations are located (exon 13 of POLE, and exon 11 of POLD1). Primers and PCR conditions have been reported elsewere. 7 Detection of point mutations in MLH1
was conducted using PCR and direct sequencing of the whole coding sequence and intron-exon boundaries for each gene and large rearrangements analysis by multiplex ligation-dependent probe amplification. 8 Sequencing was performed using a 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and data were analyzed using Sequencing Analysis, version 5.1, and Variant Reporter, version 1.1 (Applied Biosystems).
| Microsatellite genotyping and haplotype analysis
Haplotypes were constructed manually from threee single nucleotide polymorphisms (SNPs) (rs7246646, rs1363756 and rs12975011) and 11 POLD1 flanking microsatellite markers (D19S420, D19S902, D19S879, D19S867, D19S904, D19S907, D19S206, D19S921, D19S927, D19S891 and D19S887) expanding 13,818 Mb and assuming the lowest number of recombinations. References, primer sequences and PCR conditions are described in the Supporting information (Table S1 ). SNP analysis was performed by allelic discrimination using real-time PCR with TaqMan probes (Applied Biosystems). Microsatellite marker analysis was performed with one fluorescently labeled primer per set in accordance with standard procedures. Fragment analysis was performed using an ABI3130 analyzer with GeneMapper (Applied Biosystems). Mutation age was estimated with the single marker method, 9 using affected and nonaffected chromosomes from the available members of the studied families.
| RESULTS
We included 32 individuals from the four known families with the POLD1-Leu474Pro mutation: 28 were genetically tested individuals:
16 carriers and 12 noncarriers. In addition, three affected and obligated carriers were also considered. We exhausted the DNA from one mutated case that was excluded from the haplotype analysis.
| Haplotype analysis and estimation of mutation age
We found a minimum common haplotype for all 16 mutation carrier individuals analyzed from the four families. The common haplotype extended from D19S904 to D19S921 markers and represented a size of 2,995 Mb (Table 1 ; see also Supporting information, Table S2 ).
Thirty control individuals were genotyped for the microsatellite markers that define the common haplotype. We calculated the allelic frequency for each allele composing the minimum common haplotype.
The estimated frequency of the common haplotype in controls was 1.25 × 10 −6 (see Supporting information, Table S3 ). The resulting ages are four and 28 generations (100-700 years) for recombinant markers D19S867 and D19S927, respectively.
| Characterization of the clinical phenotype associated
The first family that we found with this new mutation in POLD1 was described by Valle et al. 7 This family meets Amsterdam II criteria, without alteration of the MMR system, being considered as having familial CRC type X. The mutation in this family was identified in two women affected by multiple tumors and in a healthy woman (see Supporting information, Figure S1 ). The pathogenicity assessment of this mutation was established based on various lines of evidence. The Leu474 of POLD1 is the paralog residue to the Leu424 in POLE, which is clearly pathogenic. Moreover, it is highly evolutionally conserved, in silico prediction software suggests its pathogenicity, and functional in vitro studies (in yeast) show a loss of polymerase functionality, producing a mutator phenotype. The mutation cosegregated with the disease in the family. 7 The second family found with this mutation was described by
Bellido et al. 6 This family, apparently unrelated to the previous family, met Amsterdam I criteria, with both microsatellite stable (MSS) and MSI cases (loss of MSH6), in which the mutation has been identified in seven individuals: two healthy and five diagnosed with CRC, and colonic and gastric polyps (see Supporting information, Figure S2 ).
More recently, we have identified this mutation in a third independent family. This family consists of a woman who developed CRC at The fourth independent family with the same germline mutation in POLD1 fulfilled Bethesda criteria. The proband was diagnosed with a CRC and a breast cancer at age 45 and 52 years, respectively. Her father was found to have a CRC at age 83 years. Tumor analysis of the proband showed a normal expression of the MMR proteins and MSS (see Supporting information, Figure S4 ).
In summary, 13 tumors diagnosed in 10 carrier patients (eight CRC, three endometrial cancers, a GIST and a breast cancer), an esophageal benign tumor and colorectal oligopolyposis (less than three adenomas) in another three patients were considered. The median age of cancer onset for all POLD1 mutation carriers was 48 years (range 23-80 years). The observed penetrance was 50% (40% in males and 53% in females). The cumulative risk at age 50 years was 30% (40% in males and 27% in females) ( Table 2 ).
| DISCUSSION
To our knowledge, the four Valencian families included in the pres- 
